159 related articles for article (PubMed ID: 11552898)
61. The risks and benefits of an Rx-to-OTC switch. The case of over-the-counter H2-blockers.
Oster G; Huse DM; Delea TE; Colditz GA; Richter JM
Med Care; 1990 Sep; 28(9):834-52. PubMed ID: 1976142
[TBL] [Abstract][Full Text] [Related]
62. Cisapride, metoclopramide, and ranitidine in the treatment of severe nonulcer dyspepsia.
Archimandritis A; Tzivras M; Fertakis A; Emmanuel A; Laoudi F; Kalantzis N; Anthopoulou H; Michailidis D
Clin Ther; 1992; 14(4):553-61. PubMed ID: 1525789
[TBL] [Abstract][Full Text] [Related]
63. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer.
Poynard T; Lemaire M; Agostini H
Eur J Gastroenterol Hepatol; 1995 Jul; 7(7):661-5. PubMed ID: 8590162
[TBL] [Abstract][Full Text] [Related]
64. Low yield of endoscopy in patients with persistent dyspepsia taking proton pump inhibitors.
Smith T; Verzola E; Mertz H
Gastrointest Endosc; 2003 Jul; 58(1):9-13. PubMed ID: 12838213
[TBL] [Abstract][Full Text] [Related]
65. Famotidine in the therapy of gastric hypersecretory states.
Vinayek R; Howard JM; Maton PN; Wank SA; Slaff JI; Gardner JD; Jensen RT
Am J Med; 1986 Oct; 81(4B):49-59. PubMed ID: 2877575
[TBL] [Abstract][Full Text] [Related]
66. Intravenous proton-pump inhibitors versus H2-antagonists for treatment of GI bleeding.
Huggins RM; Scates AC; Latour JK
Ann Pharmacother; 2003 Mar; 37(3):433-7. PubMed ID: 12639176
[TBL] [Abstract][Full Text] [Related]
67. Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study.
Halter F; Miazza B; Brignoli R
Scand J Gastroenterol; 1994 Jul; 29(7):618-23. PubMed ID: 7939398
[TBL] [Abstract][Full Text] [Related]
68. Observational comparative trial of the efficacy of proton pump inhibitors versus histamine-2 receptor antagonists for uninvestigated dyspepsia.
Nagahara A; Asaoka D; Hojo M; Oguro M; Shimada Y; Ishikawa D; Osada T; Kawabe M; Yoshizawa T; Otaka M; Watanabe S
J Gastroenterol Hepatol; 2010 May; 25 Suppl 1():S122-8. PubMed ID: 20586853
[TBL] [Abstract][Full Text] [Related]
69. Decision analysis of histamine H2-receptor antagonist maintenance therapy versus Helicobacter pylori eradication therapy: a randomised controlled trial in patients with continuing pain after duodenal ulcer.
Tavakoli M; Prach AT; Malek M; Hopwood D; Senior BW; Murray FE
Pharmacoeconomics; 1999 Oct; 16(4):355-65. PubMed ID: 10623364
[TBL] [Abstract][Full Text] [Related]
70. An evaluation of cimetidine and ranitidine in the pain relief and acute healing of duodenal ulcer disease.
Young MD; Lottes SR; Webb LA
Clin Ther; 1988; 10(5):543-52. PubMed ID: 2856597
[TBL] [Abstract][Full Text] [Related]
71. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia.
Finney JS; Kinnersley N; Hughes M; O'Bryan-Tear CG; Lothian J
J Clin Gastroenterol; 1998 Jun; 26(4):312-20. PubMed ID: 9649020
[TBL] [Abstract][Full Text] [Related]
72. Current indications for acid suppressants in dyspepsia.
Bytzer P; Talley NJ
Best Pract Res Clin Gastroenterol; 2001 Jun; 15(3):385-400. PubMed ID: 11403534
[TBL] [Abstract][Full Text] [Related]
73. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia.
Talley NJ; Van Zanten SV; Saez LR; Dukes G; Perschy T; Heath M; Kleoudis C; Mangel AW
Aliment Pharmacol Ther; 2001 Apr; 15(4):525-37. PubMed ID: 11284782
[TBL] [Abstract][Full Text] [Related]
74. A Randomized, Double-Blind, Pilot Study of the Effect of Famotidine on Acotiamide Treatment for Functional Dyspepsia.
Hojo M; Nagahara A; Asaoka D; Takeda T; Izumi K; Matsumoto K; Ueyama H; Shimada Y; Matsumoto K; Nojiri S; Watanabe S
Digestion; 2017; 96(1):5-12. PubMed ID: 28605740
[TBL] [Abstract][Full Text] [Related]
75. Symptomatic treatment and H. pylori eradication therapy for nonulcer dyspepsia.
Smucny J
Am Fam Physician; 2001 Nov; 64(9):1605-8. PubMed ID: 11730316
[No Abstract] [Full Text] [Related]
76. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying.
Futagami S; Shimpuku M; Song JM; Kodaka Y; Yamawaki H; Nagoya H; Shindo T; Kawagoe T; Horie A; Gudis K; Iwakiri K; Sakamoto C
Digestion; 2012; 86(2):114-21. PubMed ID: 22846371
[TBL] [Abstract][Full Text] [Related]
77. Formulary designation of cimetidine as the primary intravenous histamine H2-receptor antagonist.
Berkowitz HS
Am J Hosp Pharm; 1992 Jan; 49(1):134-5. PubMed ID: 1349201
[No Abstract] [Full Text] [Related]
78. A controlled trial of cimetidine for the treatment of nonulcer dyspepsia.
Lance P; Wastell C; Schiller KF
J Clin Gastroenterol; 1986 Aug; 8(4):414-8. PubMed ID: 3531314
[TBL] [Abstract][Full Text] [Related]
79. Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial.
Quartero AO; Numans ME; de Melker RA; Hoes AW; de Wit NJ
Scand J Gastroenterol; 2001 Sep; 36(9):942-7. PubMed ID: 11521984
[TBL] [Abstract][Full Text] [Related]
80. Histamine H2-receptor antagonists in the short- and long-term treatment of duodenal ulcer.
Thomas JM; Misiewicz G
Clin Gastroenterol; 1984 May; 13(2):501-41. PubMed ID: 6146417
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
